Who
Allison Dorval
Director
Company insider
Files Form 4 as: Director, Puma Biotechnology; Chief Financial Officer, Verve Therapeutics; Director, Jade Biosciences; Chief Financial Officer, Voyager Therapeutics; Chief Financial Officer, Insulet.
In numbers
- Trades disclosed
- 62
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $405K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 1 Dec 2014
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $84K11,610 at $7.20 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $84K11,610 at $7.20 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —258,000 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —75,000 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —33,750 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,875 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —180,000 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeutics | SEC FORM 4 Code U | —13,280 | filing |
| 13 Jun 2025filed 17 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $39K11,610 at $3.40 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 2 Apr 2025filed 3 Apr 2025 | Verve Therapeutics | SEC FORM 4 Sold | $14K3,350 at $4.15 | filing |
| 1 Apr 2025filed 3 Apr 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | Verve Therapeutics | SEC FORM 4 Code M | —11,250 | filing |
| 8 Jan 2025filed 10 Jan 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code A | —258,000 at $0.00 | filing |
| 8 Jan 2025filed 10 Jan 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Jan 2025filed 10 Jan 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 2 Dec 2024filed 3 Dec 2024 | Verve Therapeutics | SEC FORM 4 Sold | $3,130555 at $5.64 | filing |
News
Head to Head Contrast: Aurinia Pharmaceuticals (NASDAQ:AUPH) & Puma Biotechnology (NASDAQ:PBYI)PBYI · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Allison Dorval; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.